Study of MNV-201 for low-risk MDS with anemia
Part of Blood & lymphatic clinical trials.
This study tests a new therapy called MNV-201 for people with low-risk myelodysplastic syndromes (MDS) who have anemia and need regular blood transfusions. The goal is to see if this treatment can help reduce or stop the need for transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have low-risk myelodysplastic syndromes (MDS) with a certain risk score (R-IPSS ≤3).
- You have anemia and need regular blood transfusions (at least 2 units every 4 weeks for the past 8 weeks).
- You have already tried all available standard treatments for your MDS, or you cannot take them for medical reasons.
- You are not eligible for a bone marrow transplant from a donor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study carefully evaluates people with myelodysplastic syndromes (MDS) and closely related blood disorders using detailed medical, blood, and bone marrow testing. The goal is to better understand these conditions and how they progress, which may help guide future care.
This trial tests an experimental drug, HS-20106, to see if it can improve low red blood cell counts (anemia) for people with a certain type of bone marrow disorder called myelodysplastic syndromes (MDS), which is not high risk. It might be an option if you have not received certain prior treatments.
This trial tests an investigational drug called elritercept for adults with a specific type of low-risk MDS (myelodysplastic syndromes) who have anemia (low red blood cells) and need regular blood transfusions. The goal is to see if elritercept can reduce or eliminate the need for transfusions.
This study tests a new drug, momelotinib, for people with a low-risk form of myelodysplastic syndrome (MDS) who need red blood cell transfusions and have already tried one other treatment (like ESAs or luspatercept). The goal is to see if momelotinib can help reduce transfusion needs.
This trial tests an experimental drug called AND017 for people with a certain type of myelodysplastic syndrome (MDS) that is low-risk and not linked to a chromosome 5 deletion. The goal is to see if AND017 can help improve low red blood cell counts (anemia) and reduce or avoid the need for blood transfusions.
This trial tests whether a structured lifestyle program can help people with low-risk myelodysplastic syndromes (MDS) manage their health better. It mainly targets adults who are not getting frequent blood transfusions and have low hemoglobin levels.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.